John S. Sundsmo, Ph.D.

P.O. Box 927,
Sausalito, CA. 94966.
TEL: 760-994-7028
jssund@gmail.com

 

 

Board Positions
Board Member, Drug Risk Solutions, Saratoga Springs, NY (1999-2001) – testing, drugs of abuse
Board Member, International Medical Innovations, Birmingham, AL (1999-2001) – Parkinson’s
Chairman of the Board, TransCell Therapeutics, Inc., Nashville, TN (2001-2003) –inflammation
Board Member, BioCom, San Diego, CA – the biotech industry organization (2008-2009)

Biopharmaceutical Positions (1983-2012)


Vice President, R&D and Intellectual Property

Stellar

Stellar Biotechnologies, Inc. (2010- 2012)

    • Product Area: KLH immune status diagnostics and vaccine carriers
    • Joining as a business consultant through the NSF business Innovation Accelerator, immediate recognized needs included establishing an intellectual property (IP) platform and IP strategy supportive of business development and private financings; which transitioned rapidly to Acting-COO responsibilities for managing day-to-day new product development initiatives, liaison with the Bayer Innovation Group (Bayer Pharmaceuticals, Wuppertal, DE) and translation and scale-up of the first new manufacturing process campaign; with subsequent (more recent) redirected business needs next including intellectual property portfolio development, extramural scientific liaison and support of business development in negotiating terms of collaborative agreements, contracts, MTAs, CDAs; and with grant writing designed to promote the company’s position in the science and promote relationships with customers, the scientific, business and investment communities, all in support of follow-on financings for this now publicly traded small-cap company.
    • www.StellarBiotech.com

President

PrimeGen

PrimeGen Biotech, LLC, Irvine, CA (2007-2009)

    • Stem cell regenerative medical products: iPS cells, adipose derived and germ line
    • Joining as a Director of Intellectual Property, within four months approached by the Chairman of the Board to assume responsibilities as President, successfully managed a skilled team of hard-working talented stem cell scientists in a successful international competition to be first to translate viral-induced pluripotent stem cell (iPS) technologies into non-viral safe clinical alternatives; and to be the first to isolate human testis germ line stem cells; while preserving morale during a significant staff down-sizing from 45 to 26 and managing budgets ($6M/yr), building an intellectual property strategy, drafting patents and conducting business development liaison partnering initiatives in the US, UK, Italy and Germany for manufacturing stem cell clinical supplies in UK and Switzerland with clinical trials in the UK and Italy.
    • WO2009032456, NON-VIRAL DELIVERY OF TRANSCRIPTION FACTORS THAT REPROGRAM HUMAN SOMATIC CELLS INTO A STEM
      CELL-LIKE STATE
      Business Summary

Chief Executive Officer

TransCell Therapeutics, Inc., Nashville, TN  (2002-2006)

    • Cell penetrable peptide-based non-steroidal anti-inflammatory agents to inhibit karyopherin-mediated nuclear translocation of pro-inflammatory transcription factors
    • Treatments for age-related macular degeneration
    • Liaison: Univ. of Miami and Indiana University Medical Schools
    • Corporate Summary

Chief Science Officer

International Medical Innovations, Birmingham, AL – (1998-2004)

Co-Founder, Director, Intellectual Property and Senior Scientist

Phage Therapeutics, Inc., Bothell, WA – (1997-2001)

    • Bacteriophage biopharmaceutical agents for treating multi-drug resistant Staphylococcal, Pseudomonas and Mycobacterial agents
    • Liaison: Georgian Academy of Sciences and Eliava Institute(T’blisi)

RACE Pharmaceuticals, Inc., Bothell, WA – (1996-2001)

    • Small molecule anti-fungal agents in-licensed from the DuPont-Merck joint venture

VP Research & Product Development

Lifetrac Corporation, Irvine, CA – (1988-1989)

    • Dx/Rx Type-1 insulin-dependent diabetes (IDDM)
    • Personalized Oncology Diagnostics
    • Liaison: Toronto University, University of Chicago

Manager

Extramural Research, Triton Biosciences Div. Shell Oil, Alameda, CA – (1987-1988)

    • Rx Oncology drug development candidates
    • Liaison: University of Iowa, Dartmouth University, University of Chicago, University of California

Senior Scientist

Collagen Corporation, Palo Alto, CA – (1986-1987)

    • Zyderm, Injection medical device

Manager

Product Development, Synbiotics Corporation, San Diego, CA – (1984-1986)

    • Veterinary immunodiagnostics
    • Liaison: DuPont de Nemours; American Home Products

Recent Community Service
NSF SBIR Study Section Peer Reviewer: Drug Development, Diagnostics and Medical Devices, Technology Development, Drug Screening  (2008-present).
NSF Innovation Accelerator, Business Development Mentor (2009-2010).

Professional Organizations
American Association of Immunologists (1979-present)

Patents and Applications (Inventor)
US 4,760,131. Sundsmo, J.S., G. Ksander, R. Ross, and J. McPherson.  Novel Wound Healing Composition.
EPA 243,179, AU 8,771,914; Sundsmo et al. Soft Tissue Wound Healing Composition Comprises Fibrillar Collagen, Heparin, or Heparin-like Glycosaminoglycan and Chemotactic, Growth or Differentiation Factor.
JP63054328 (A). Sundsmo, J.S., Ksander, G.A. et al. Wound Healing Composition and Wound Bandage Therewith.
AU7191487. Sundsmo, J.S., Ksander, G.A. et al. Wound Healing Composition and Wound Dressing Containing It.
AT81780 (T). Sundsmo, J.S., Ksander, G.A. et al. Wundeheilende Zusammensetzung.
US 6,478,750. Morrison, J.F., Morrison, P.A., Selavka, C.M., Eden, T.M., Thuss, C.B., Hopper, K.C., Sundsmo, J.S. Hair Collection Device for Drug Testing.
US7345031 (B2). Christian, S. and J. Sundsmo. Pharmaceutical DopamineGlycoconjugate Compositions and Methods of Their Preparation and Use.
US 20020198748. Eden, T. and J. Sundsmo. System and method for implementing an employee-rights-sensitive drug free workplace policy.
US 20050037386WO2005039381 (A2).  Morrison, J.F., Sundsmo, J.S., Selavka, C.M., Brill, D.H. Composition and Processes for Analysis of Pharmacologic Agents in Biological Samples.
US20050250739. Christian, S. and J. Sundsmo. Pharmaceutical DopamineGlycoconjugate Compositions and Methods of Their Preparation and Use.
WO 2009032456 (A2) Kannemeier, C., Marh, J.S.W., Howerton, K., Sundsmo, J.S. Non-Viral Delivery of Transcriptional Factors that Reprogram Human Somatic Cells into a Stem Cell-Like State.
WO 2009140655 (A1) Kannemeier, C., Pham, J., Javier, C., Sundsmo, J.S. Methods for Efficient Viral Reprogramming of Somatic Cells into Stem Cell-Like Pluripotent Cells.
US13/573,149 Chow, H., Sundsmo, J.S. and Sagermann, M. Hemocyanin Compositions, Methods for their Control and Uses.

SELECTED PUBLICATIONS
RECENT ABSTRACTS:
Sundsmo, J.S., Chow, H. and M. Sagermann. 2012. Keyhole Limpet Hemocyanin (KLH) N-Glycans Share Similar Structural Features with Saccharides of Schistosoma, Trypanosoma, Leishmania, Cryptococcus, Aspergillis, Candida, E. coli, Salmonella, Clostridium and Hepatitis C virus (HCV). ICCAC, San Francisco, September 9, 2012.
Chow, H., Sagermann, M. and J. S. Sundsmo. 2012. Keyhole Limpet Hemocyanin (KLH): A Unique Unlikely Pharmaceutical Product. Immunotherapeutics and Vaccine Summit, Cambridge, MA. Aug. 13-16, 2012.
Lebec, H., Hock, M.B., Sundsmo, J., Mytych, D., Chow, H., Carlock, L., Joubert, M.K., Haynes, J. and J. Bussiere. T-cell Dependent Antibody Responses in the Rat: Forms and Sources of Keyhole Limpet Hemocyanin Matter. Society of Toxicology. San Antonio, TX. March 10-14, 2013.
SELECTED REVIEWS:
Monteiro, M.A., Ma, Z., Bertolo, L., Jiao, Y., Arroyo, L., Mallozzi, M., Vedantam, G., Sagermann, M., Sundsmo, J. and H. Chow. 2013. Polysaccharide-based Clostridium difficile vaccines. Expert Reviews in Vaccine Science, in press, January 2013 issue.
Sundsmo, J.S. 1987. The Use of "Magic Bullets for the Treatment of Cancer: Monoclonal Antibody Immunotoxins. Triton Corp. Research and Development Notes. January, 1987.
Sundsmo, J.S. and D.S. Fair. 1983. Relationships among the complement,kinin, coagulation, and fibrinolytic systems. Springer Sem. Immunopathol. 6:  231-258.
Sundsmo, J.S. and D.S. Fair. 1983. Relationships among the complement, kinin, coagulation, and fibrinolytic systems. Springer Semin Immunopathol. 6(2-3):231-58.
SELECTED ORIGINAL ARTICLES:
Jiang C, Wan X, Jankovic J, Christian ST, Pristupa ZB, Niznik HB, Sundsmo JS, Le W. 2004. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clin Neuropharmacol. Mar-Apr;27(2):63-73.
Ksander GA, Sawamura SJ, Ogawa Y, Sundsmo J, McPherson JM. 1990. The effect of platelet releasate on wound healing in animal models. J Am Acad Dermatol. May; 22(5 Pt 1):781-91.
DeLustro, F.S., T. Smith, J.S. Sundsmo, G. Salem, S. Kincaid, and L. Ellingsworth. 1987. Reaction to Injectable Collagen Results in Animal Models and Clinical Use. Plastic and Reconstructive Surgery 79: 581-592.
Sundsmo, J.S., R.A. Papin, L. Wood, S. Hirani, N. Waldeck, B. Buckingham, A. Kershnar, M. Ascher, and M.A. Charles. 1985. Complement activation in type 1 human diabetes. Clin. Immunol. Immunopathol. 35: 211-225. [First demonstration: Complement activation in diabetes.]